ADAP HCV Decision Tree

NASTAD continues work to ensure that individuals coinfected with HIV and hepatitis C virus (HCV) can gain access to curative treatments for HCV via the Health Resources and Services Administration’s (HRSA) Ryan White HIV/AIDS Program’s (RWHAP) AIDS Drug Assistance Programs (ADAPs). While the number of ADAPs that include one or more direct-acting antiviral (DAA) HCV treatments on their formulary continues to increase, many ADAPs still face challenges in optimizing uptake of HCV treatment among HIV/HCV coinfected clients.

Utilization data suggests that the broader HCV health care landscape remains confusing for clients and providers to navigate. Many providers do not maximize all available HCV treatment opportunities, instead relying solely on pharmaceutical companies’ patient assistance and cost-sharing assistance programs. NASTAD has developed a decision tree for providers to illustrate and clarify the myriad treatment coverage options available to people living with HIV and HCV, including ADAP. Please note: If the decision tree doesn't load immediately, please refresh the page.

ADAPs are encouraged to share this resource with local HIV/HCV service providers, including those who work outside of the RWHAP.